Primary pelvic soft tissue sarcomas (PELVISARC): outcomes from the TransAtlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)
Marco Fiore(Fondazione IRCCS Istituto Nazionale dei Tumori), Jiping Wang, Antoine Bouchard‐Fortier(University of Calgary), Dimitri Tzanis(Université Paris Cité), Dario Callegaro(Fondazione IRCCS Istituto Nazionale dei Tumori), Myles Smith(Royal Marsden NHS Foundation Trust), Vittorio Quagliuolo(Humanitas University), Paul Sargos, Matthieu Faron(Institut Gustave Roussy), Kenneth Cardona(Emory University), Ferdinando Cananzi(Humanitas University), Marko Novak(Peter MacCallum Cancer Centre), Gary N. Mann, Chiara Colombo(The University of Texas MD Anderson Cancer Center), Mario Terlizzi(Institut Gustave Roussy), S. Valeri, Shintaro Iwata(National Cancer Centre Japan), Max Almond(Queen Elizabeth Hospital Birmingham), Giovanni Grignani(Candiolo Cancer Institute), Chandrajit P. Raut(Dana-Farber Cancer Institute), Sylvie Bonvalot(Dana-Farber Cancer Institute), Carolyn Nessim(University of Ottawa), D. Strauß(Royal Marsden Hospital), Audrey Michot, Charles Honoré(Institut Gustave Roussy), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Laura Samà(Humanitas University), Winan J. van Houdt(Diakonessenhuis hospital), Dorian Yarih García-Ortega, Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Mark Fairweather(Brigham and Women's Hospital), Dan G. Blazer(Duke University), Sergio Quildrian(Universidad de Buenos Aires), Stefano Redaelli(Fondazione IRCCS Istituto Nazionale dei Tumori), Catherine Sarre-Lazcano(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Jacek Skoczylas(The Maria Sklodowska-Curie National Research Institute of Oncology), David Gyorki(The University of Melbourne)
Cited by 5
Related Papers
A Short Physical Performance Battery Assessing Lower Extremity Function: Association With Self-Reported Disability and Prediction of Mortality and Nursing Home Admission
|Journal of Gerontology|1994|9.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k